No clinical trial of PD treatment(s) has yet examined whether improvement of PersD, either at diagnostic or trait level, corresponds to improvement in PD symptoms themselves (Markowitz et al., 2015) .
In addition, the ability of brief, targeted, panic-focused psychotherapies to alter PersD has rarely been evaluated. In the only trial of which we are aware, CBT for PD and imipramine were equivalently effective at improving self-reported PersD traits from the Wisconsin Personality Disorders Inventory, although PersD was not rigorously diagnosed, remission rates were not reported, and the overall within-group treatment effects were small (average d = 0.28) (Hofmann et al., 1998) .
Although some recovery from PersD has also been reported during short-term treatments for PTSD (Markowitz et al., 2015) and major depressive disorder (Cyranowski et al., 2004; Fava et al., 2002; Keefe, Webb, & DeRubeis, 2016) , change in diagnostician-rated PersD has not been evaluated in PD treatment.
Understanding the degree to which PersDs are modified by successful treatment of PD might shed light on whether comorbid PersD reflects a syndrome meaningfully separate from acute PD. It is also clinically important to know whether PD patients presenting with comorbid PersD require additional treatment for the PersD. Furthermore, different treatments for PD, such as Panic-Focused Psychodynamic Psychotherapy (PFPP) (Milrod, Busch, Cooper, & Shapiro, 1997) and CBT for panic (Craske, Barlow, & Meadows, 2000) , might have differential efficacy in treating comorbid PersD (Barber, Muran, McCarthy, & Keefe, 2013; Johansen, Krebs, Svartberg, Stiles, & Holen, 2011; Mil- rod, Leon, Barber, Markowitz, & Graf, 2007) .
We examined these questions in the Cornell-Penn Study of Psychotherapies for Panic Disorder, a two-site randomized controlled trial that compared CBT, PFPP, and ART in a 2:2:1 ratio for 201 patients with primary DSM-IV PD with or without agoraphobia (Milrod et al., 2016) . For the purposes of the present analysis, we eliminated the ART control group, for which data were sparse because this group was initially smaller and had a significantly higher (41%) drop-out rate relative to CBT and PFPP (25 and 21%, respectively) . This rate of dropout was particularly pronounced among more severe panic symptomatic patients (69%), which was not the case for either CBT or PFPP. Moreover, patients with worse symptom trajectories tended to drop out of the trial significantly more. Completer ART patients were thus a relatively less symptomatic and (seemingly) more successful subsample, who would be unrepresentative for the present analyses.
We hypothesized a priori that PFPP would be superior to CBT in improving PersD criteria in patients with more severe PersD, as indexed by meeting more baseline PersD criteria. PFPP is designed to address some of the psychological processes that are hypothesized to underlie both PD and some aspects of PersD . In particular, PFPP specifically targets dysregulated attachment that may sensitize panic patients to actual or imagined losses of attachment figures (Milrod et al., 2014) , and the maladaptive defense use that prevents patients from experiencing and working with meanings surrounding panic (Busch, Shear, Cooper, Shapiro, & Leon, 1995) . Both attachment dysregulation and defense use are especially severe in PersD (Levy, Johnson, Clouthier, Scala, & Temes, 2015; Perry & Bond, 2005) . Furthermore, improvements in attachment, defense use, and insight into defense use have been observed to mediate symptomatic improvements in PersD therapy trials (Johansson et al., 2010; Perry & Bond, 2012; Rossouw & Fonagy, 2012) and naturalistic studies (Zanarini, Frankenburg, & Fitzmaurice, 2013 
Methods
201 patients (aged 18-70 years) were recruited at Weill Cornell Medical College ("Cornell") and the University of Pennsylvania ("Penn") 1 and randomized to treatment: PFPP, CBT, or ART in a 2:2:1 ratio. Of these, 118 patients completed CBT or PFPP and are the focus of this manuscript. All patients provided informed, written consent. Patients received study treatment gratis. Both sites' institutional review boards approved the protocol (ClinicalTrials.gov identifier: NCT00353470).
Patients were included in the trial if they experienced one or more spontaneous panic attacks for the month before trial entry, and qualified for a DSM-IV PD diagnosis with or without agoraphobia determined as per the ADIS-IV Lifetime version (Brown, DiNardo, & Barlow, 2004) . Cross-site agreement on ADIS ratings for panic severity (with "4 ″ indicating diagnostic threshold) was excellent (ICC = 1.00). Assessors from both sites rated two cases together annually to prevent drift, in addition to within-site reliability meetings.
Non-study psychotherapy was prohibited. Medications were permitted if stable for at least two months at presentation, and were recorded, held constant, and monitored during the trial. Exclusion criteria were: active substance dependence (less than 6 month's remission), history of psychosis or bipolar disorder, acute suicidality, or organic mental syndrome (Milrod et al., 2016) .
Treatments
PFPP is based on the central assumption that panic symptoms have a partly unconscious psychological meaning. It explores feelings and subjective content of panic episodes, so the patient can begin to address these meanings rather than experiencing conflicts physically as somatic anxiety leading to panic (Milrod et al., 1997) . The therapy helps patients understand and alter core conflicts (e.g., regarding attachment and dependency) to avert future panic vulnerability. CBT for PD followed a modified version of the Panic Control Therapy protocol (Craske et al., 2000) , entailing education about panic, correction of maladaptive thoughts about anxiety and body sensations, and both in-session and homework interoceptive exposures to bodily sensations designed to mimic those experienced during panic (Craske et al., 2000) . Both psychotherapies comprised 24 sessions delivered twice weekly (12 weeks). Additional information on treatments, including training, supervision, and adherence monitoring, can be found in Milrod et al. (2016) .
Measures
Structured Clinical Interview for Diagnosis for Axis-II Disorders (SCID-II) (First, Gibbon, Spitzer, Williams, & Benjamin, 1997) . This structured clinical interview assesses presence of PersD criteria and diagnoses as defined by DSM-IV. Primary analyses of relationships between change in PersD, panic improvement, and treatment condition employed the number of criteria met rather than PersD diagnosis for reasons of statistical power (MacCallum, Zhang, Preacher, & Rucker, 2002) , following research suggesting that DSM-IV PersD reflects a continuum of illness rather than categorical taxonomies (Harford, Chen, & Grant, 2014; Harford et al., 2013; Haslam, Holland, & Kuppens, 2012) . For descriptions of PersD diagnostic recovery, we examined both remission (defined as an individual falling under diagnostic threshold), and a stricter PersD "recovery" criterion defined by the Collaborative Longitudinal Personality Disorders Study as meeting two or fewer criteria in originally diagnosed PersDs (Gunderson et al., 2011) . Trained, independent masters' level diagnosticians blinded to treatment condition administered the interviews.
Cross-site inter-rater reliability for number of PersD criteria scored as present on the SCID-II was excellent (ICC = 0.92), and good for PersD Clusters A, B, and C, respectively (ICC A = 0.82 / ICC B = 0.87 / ICC C = 0.86).
Panic Disorder Severity Scale (PDSS) (Shear et al., 1997) . The primary outcome measure of the study was the PDSS, a diagnosis-based, composite, global rating of PD severity that has acceptable psychometric properties (Shear et al., 1997) . Inter-rater reliability was excellent (ICC = 0.95). Analyses for this manuscript employed pre-to-post treatment change scores.
Analyses
All statistical analyses were conducted within the R statistical computing language (R Core Team, 2016) . All regression analyses were accomplished using robust regressions as implemented in the R package "robustbase" (Cantoni & Ronchetti, 2001; Huber & Ronchetti, 2009; Koller & Stahel, 2016; Maechler et al., 2016) . As per Huber and Ronchetti, robust regression was used for its superior properties of robustness against multivariate outliers and deviation from homoscedasticity (Huber & Ronchetti, 2009 ).
Among CBT and PFPP trial completers (n = 118), 4 patients (3.4%)
were missing baseline SCID-II criteria data, and 25 patients were missing termination SCID-II criteria data (21.2%). Apart from assessor error, missing termination SCID-IIs among completers were missing because collection of the trial's primary outcome measure (the PDSS) was prioritized over secondary measures in subjects for whom it was difficult to complete the full termination assessment. Thus, for treatment completers both baseline and termination SCID-II missingness was presumed to be missing at random.
For the treatment completers (n = 118) a multiple-imputation based approach to the missing baseline and termination SCID-II data was undertaken using the R packages "mice" and "CALIBERrfimpute."
We employed multiple imputations by chained equations using draws from a random-forest developed distribution, creating 100 iterations of 50 imputed datasets, with analyses pooled together using Rubin's rule (Shah, Bartlett, Carpenter, Nicholas, & Hemingway, 2014; van Buuren & Groothuis-Oudshoorn, 2011) . All analyses were repeated using only completer patients providing completely observed data, and in no instances did results between the multiple imputation and complete data approaches substantively differ (i.e., significant results becoming nonsignificant, or vice-versa).
All analyses controlled for baseline number of SCID-II criteria met, baseline PDSS score, and a main effect of site. Analyses that included treatment condition used CBT as the reference group. Site was originally included as an interaction term with the focal predictors in all following analyses (e.g., did the relationship between PDSS and SCID-II change differ by site), but it was ultimately removed in analyses for which it lacked statistical significance (P < 10) in order to conserve power and retain interpretability. However, the main effect of site was maintained throughout all analyses. Tables 1 and 2 , respectively. The average completer with a PersD met criteria for 1.6 (SD 0.8) PersD diagnoses. There were no site or site by treatment differences in PersD (Milrod et al., 2016) . Among completers with an SCID II PersD, the most common criteria endorsements were Cluster C (mean 6.1), followed by Clusters B (3.7) and A (2.5). Rates of individual PersD diagnoses (see Table 3 ) were comparable to those found in the only other PD psychotherapy trial (to our knowledge) that employed the SCID-II to formally diagnose PersD . Baseline SDS* (Leon, Shear, Portera, & Klerman, 1992) 13.3 (6.3) 17.1 (7.4)
RESULTS

Description of sample
Correlation between PersD criteria change and panic symptom change
Baseline HAM-D** (Hamilton, 1960) Childhood trauma sum* (Lizardi et al., 1995) 3.0 (1.1) 3.6 (1.7)
Baseline BBSIQ (Clark et al., 1997) 1.9 (0.4) 1.9 (0.3)
Baseline RF (Rudden, Milrod, & Target, 2005) 4.3 (1.2) 4.2 (1.3)
Baseline PSRF (Rudden, Milrod, Target, Ackerman, & Graf, 2006) 3.4 (1.1) 3.6 (1.2)
Notes: ✝ P < .10; * P < .05; ** P < . were not significantly related to panic symptom change, controlling for change in Cluster C.
Treatment-related changes in PersD 2.3.1 Remission of PersDs
Overall, 37.0% (95% CI: 24.6 to 51.3%) of PersD patients fell below Table 3 shows remission rates on a per-PersD basis.
As expected, rates of recovery from PersD (i.e., having two criteria or less) were much lower than SCID-II remission rates. Only 16.7%
(95% CI: 8.4 to 29.8%) of patients (n = 9) experienced recovery from all baseline PersDs. SCID-II PersD "remission" thus often reflected falling Notes: ✝ P < .10; * P < .05; ** P < .01.
TA B L E 2 Baseline SCID-II PersD criteria endorsed by PersD and non-PersD patients
Mean (SD)
No
TA B L E 3
PersD diagnoses at baseline and after treatment for completers (n = 118) 
Changes in PersD criteria
Patients One possibility is that these differential changes in PersD traits were confounded with declines in acute panic symptomatology. As a statistical check, we re-ran all PersD criteria outcome analyses using a measure of PersD criteria change that had been residualized on (i.e., controlling for) PDSS panic symptom change. The chief interaction between PersD criteria and treatment condition remained statistically significant (P = .009). Estimated declines in residualized PersD criteria folded across the two treatments were marginally smaller, at 1.3 criteria for patients without PersD, and 5.0 criteria for patients with PersD.
DISCUSSION
Comorbid PersD that presents in the context of primary PD with or without agoraphobia only partially resolves during brief, 12-week PD psychotherapies. Over 80% of patients did not recover from their
PersD over the course of 3 months of biweekly panic-focused psychotherapy, indicating that short-term panic-focused psychotherapies are insufficient to treat comorbid PersD.
Although patients lost more PersD criteria after experiencing improvement in panic symptoms compared to those who did not experience improvement, the effect size of this relationship was moderate, Change in Cluster C PersD criteria uniquely correlated with improvement of PD symptoms, whereas change in Clusters A and B did not. This may be because Cluster C, the "anxious" Cluster, encompasses a set of syndromes partly contiguous with symptoms of anxiety disorders (Marques et al., 2012; Torvik et al., 2016 ) that may improve with targeted anxiety treatment. In the Collaborative Longitudinal Personality Disorders Study, the six-month stability of schizotypal and borderline PersD did not substantively differ from that of avoidant and obsessive-compulsive PersD (Sanislow et al., 2009) , and remission from Cluster C PersDs over time was only marginally swifter than that of borderline PersD (Gunderson et al., 2011) . Thus, the higher corre- 
Limitations
The analysis of PersD outcomes, although planned, was not the primary focus of this trial. In addition, these analyses are limited to change during acute treatment, and do not include follow-up results. As such, all findings should be viewed as preliminary results that can best serve for hypothesis-generation for future treatment trials, in which recruitment and stratification can balance presence of primary anxiety disorders with PersDs across treatments.
Furthermore, due to power considerations concerning the relatively small absolute number of completer patients with PersD diagnoses (n = 54), our analyses of differential treatment efficacy concerned PersD criteria rather than PersD diagnostic remission.
Although these analyses were statistically optimal, this limits the clinical utility of our findings for those who approach PersD categorically or prototypically rather than dimensionally (Shedler et al., 2010; Spitzer, First, Shedler, Westen, & Skodol, 2008; Westen, Shedler, & Bradley, 2006 In this trial, we did not collect data on possible mediators of PersD improvements, such as attachment or defense mechanism use (Levy et al., 2015; Perry & Bond, 2005) . As such, although we would hypothesize that the reason why PFPP was superior to CBT for improving more severe PersD was because PFPP better targeted these personality facets, our results do not directly address this hypothesis.
A trial including repeated measurements of both PersD symptoms and putative mediators during treatment would be revelatory on this question.
CONCLUSION
In the context of PD treatment, PD and PersD appear to be clinically dissociable diagnoses. Although PersD generally improves during psychotherapy for PD, a majority of completers with PersD retain at least one PersD diagnosis following treatment, and less than 20% meet PersD recovery criteria. Patients with more severe PersDs, especially
Cluster B, may experience more PersD improvement in PFPP as compared to CBT, a preliminary finding that requires replication.
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ENDNOTES
1 The primary outcome paper for this trial indicated that treatment attrition was not missing at random (NMAR), such that patients with worse panic symptom outcome trajectories were more likely to drop out of treatment (Milrod et al., 2016) . Due to the NMAR dropout pattern, an imputationbased approach to missing data for trial dropouts would result in biased estimates. As the SCID-II was only administered before and after treatment, statistical methods to account for NMAR dropout could not be employed. Moreover, due to its high rates of dropout, this means that ART trial completers were particularly likely to represent an unusually successful and mildly ill subgroup of patients from this treatment, further speaking to its exclusion from these analyses. Thus, only CBT and PFPP patients fully completing the trial were used for the following analyses (n = 118).
2 When entered into the same regression, improvement in the criteria for each Cluster C diagnosis significantly correlated with improvements in panic symptoms (P < .05), suggesting that general improvement in Cluster C was correlated with symptom change on the PDSS.
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